Expanded Programme on Immunization

Expanded Programme on Immunization
Name	Expanded Programme on Immunization
Formation	1974
Founder	World Health Organization
Headquarters	Geneva
Region served	Worldwide
Parent organization	World Health Organization

Contents

Expanded Programme on Immunization

The Expanded Programme on Immunization was launched to coordinate global efforts to increase childhood vaccination coverage and reduce vaccine-preventable diseases. It involved collaboration among World Health Organization, United Nations Children's Fund, United Nations, World Bank, Bill & Melinda Gates Foundation, and numerous national ministries such as Ministry of Health (United Kingdom), Ministry of Health and Family Welfare (India), and Ministry of Health (Brazil).

History and Development

The programme was proposed at meetings including sessions of the World Health Assembly and endorsed by leaders at Alma-Ata Conference and initiatives linked with Smallpox eradication campaign and the Global Polio Eradication Initiative. Early implementation drew on expertise from institutions like Centers for Disease Control and Prevention, Johns Hopkins University, Imperial College London, London School of Hygiene & Tropical Medicine, and funding models influenced by International Monetary Fund, Gavi, the Vaccine Alliance, and philanthropic actors such as Rockefeller Foundation. Regional expansion involved coordination with entities such as the Pan American Health Organization, African Union, European Commission, and national programmes in countries including India, Nigeria, Pakistan, China, Brazil, Ethiopia, Indonesia, and Philippines.

Primary goals aligned with resolutions at the World Health Assembly and targets from the Millennium Development Goals and later the Sustainable Development Goals were to increase immunization coverage, reduce child mortality, and control vaccine-preventable diseases. Strategic priorities referenced frameworks like the Global Vaccine Action Plan and collaborations with research partners such as Oxford University, Harvard University, Karolinska Institutet, and Pasteur Institute to prioritize vaccines for diseases tracked by organizations like Global Polio Eradication Initiative and Rotavirus Surveillance Network.

The programme promoted routine use of vaccines such as Bacillus Calmette–Guérin from Pasteur Institute, diphtheria–tetanus–pertussis (DTP) combinations used in campaigns by Médecins Sans Frontières, oral polio vaccine pioneered in trials by Albert Sabin and supported by Jonas Salk-era institutions, measles vaccines developed at Johns Hopkins University trials, and later additions including Haemophilus influenzae type b, hepatitis B, pneumococcal conjugate vaccine researched at Boston Children's Hospital, rotavirus vaccines trialed with partners like Centers for Disease Control and Prevention, and human papillomavirus vaccines introduced following work at National Cancer Institute. Implementation drew on cold chain technologies supplied by manufacturers and logistics providers including United Parcel Service, DHL, and procurement via UNICEF Supply Division and Pan American Health Organization Revolving Fund.

Delivery strategies combined routine immunization in primary care settings run by facilities such as Kaiser Permanente-modeled clinics, outreach campaigns modeled after the Smallpox eradication campaign logistics, and mass immunization days coordinated with electoral-style mobilization used in India's pulse polio campaigns. Supply chain and cold chain solutions were informed by engineering partnerships with Siemens, GE Healthcare, and Danfoss, while information systems drew on platforms from World Health Organization, UNICEF, Gavi, the Vaccine Alliance, and academic informatics projects at Massachusetts Institute of Technology and Carnegie Mellon University. Workforce capacity building leveraged training curricula from London School of Hygiene & Tropical Medicine, Harvard T.H. Chan School of Public Health, and operational research by International Vaccine Institute.

Monitoring used indicators endorsed by World Health Organization and data collected by national systems that report to United Nations Children's Fund and specialized networks like the Global Polio Laboratory Network and Measles & Rubella Laboratory Network. Evaluation studies published with authors from Lancet, New England Journal of Medicine, Nature, and BMJ demonstrated reductions in mortality consistent with analyses by Institute for Health Metrics and Evaluation and global burden assessments by Global Burden of Disease Study. Independent reviews by auditing bodies including World Bank evaluations and programme assessments by Independent Monitoring Board frameworks informed course corrections and resource allocations coordinated with Gavi, the Vaccine Alliance and bilateral donors like United States Agency for International Development, UK Department for International Development, and German Federal Ministry for Economic Cooperation and Development.

The programme faced criticisms linked to supply shortages documented in reports from UNICEF Supply Division, cold chain failures investigated by World Health Organization technical advisory groups, vaccine hesitancy explored in sociology studies at University of Oxford and University of Cambridge, and equity gaps highlighted by Human Rights Watch and Amnesty International. Security threats in conflict zones such as Syria, Afghanistan, Iraq, and regions affected by Ebola virus epidemic in West Africa complicated delivery, while intellectual property debates involving World Trade Organization agreements and pharmaceutical corporations like GlaxoSmithKline, Pfizer, Merck & Co., and Sanofi influenced access. Operational critiques referenced performance measured in evaluations by Audit Commission-style reviewers, and calls for integration with broader maternal and child health services cited models from Integrated Management of Childhood Illness and partnerships with UNFPA and World Bank programmes.

Category:Vaccination programs